Blog
RSS FeedPosted by Michael Wonder on 18 Oct 2024
Fresenius Kabi launches Tyenne, the first and only approved tocilizumab biosimilar in Canada
17 October 2024 - Tyenne is the first and only tocilizumab biosimilar to be launched in Canada. ...
Posted by Michael Wonder on 18 Oct 2024
Government of Canada announces new appointment to the Patented Medicine Prices Review Board
17 October 2024 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine ...
Posted by Michael Wonder on 17 Oct 2024
Incyte announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis and non-segmental vitiligo
16 October 2024 - First and only treatment approved by Health Canada for repigmentation of non-segmental vitiligo. ...
Posted by Michael Wonder on 17 Oct 2024
Acadia Pharmaceuticals announces Health Canada approval of Daybue (trofinetide) for the treatment of Rett syndrome
16 October 2024 - Daybue is the first and only therapy approved in Canada for the treatment of Rett syndrome, a ...
Posted by Michael Wonder on 15 Oct 2024
Lantern Pharma’s investigational drug candidate, LP-184, receives fast track designation in glioblastoma from the FDA
15 October 2024 - A Phase 1b/2a clinical trial for recurrent glioblastoma is targeted to start in late 2024/early 2025. ...
Posted by Michael Wonder on 11 Oct 2024
Roche Canada announces Columvi (glofitamab for injection) is publicly reimbursed in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland
9 October 2024 - Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian ...
Posted by Michael Wonder on 07 Oct 2024
Health Canada approves label expansion for Telix’s Illuccix to include patient selection for PSMA targeted therapy
4 October 2024 - Telix Pharmaceuticals today announces that Health Canada has approved the use of Illuccix (kit for the ...
Posted by Michael Wonder on 02 Oct 2024
Clinuvel files Canadian new drug submission for Scenesse in EPP
30 September 2024 - Patient special access program continues during Health Canada review. ...
Posted by Michael Wonder on 29 Sep 2024
Vertex announces Health Canada acceptance of new drug submission for vanzacaftor/tezacaftor/deutivacaftor, a next in class triple combination treatment for cystic fibrosis
26 September 2024 - Vertex Pharmaceuticals today announced that Health Canada has accepted for review its new drug submission for ...
Posted by Michael Wonder on 26 Sep 2024
Health Canada grants marketing authorisation of first CRISPR/Cas9 gene edited therapy, Casgevy (exagamglogene autotemcel), for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia
25 September 2024 - First regulatory authorisation of a CRISPR-based gene-editing therapy in Canada. ...
Posted by Michael Wonder on 26 Sep 2024
Pfizer Canada and BioNTech receive Health Canada approval of Omicron KP.2 variant adapted COVID-19 vaccine
24 September 2024 - Omicron KP.2 variant adapted vaccine Comirnaty is now authorised in Canada for individuals 6 months of age ...
Posted by Michael Wonder on 25 Sep 2024
Moderna receives Health Canada approval for updated COVID-19 vaccine targeting KP.2 variant of SARS-COV-2 for ages six months and older
17 September 2024 - Spikevax is the first updated COVID-19 vaccine authorised in Canada for 2024-2025, offering a timely solution to ...
Posted by Michael Wonder on 22 Sep 2024
Men get breast cancer, too. But they can't always access new drugs.
21 September 2024 - Breast cancer is widely researched, but some men suffering from the illness say they can’t benefit. ...
Posted by Michael Wonder on 21 Sep 2024
New COVID-19 vaccine by Moderna approved by Health Canada
17 September 2024 - Health Canada has approved an updated version of Moderna’s COVID-19 vaccine, a decision that means some ...
Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...